Patents Assigned to The Institute for Cancer Research
  • Conditional immortalization of cells
    Patent number: 6399384
    Abstract: A recombinant, or genetically engineered, mammalian cell, comprises a conditionally-inducible oncogene and an exogenous polynucleotide encoding the catalytic sub-unit of the telomerase complex. The recombinant cells are useful in therapy, to replace lost or damaged cells.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: June 4, 2002
    Assignees: Reneuron Limited, Ludwig Institute for Cancer Research
    Inventor: Parmjit Jat
  • Isolated proteins having retinol dehydrogenase activity, and which associate with retinol binding receptors
    Patent number: 6399344
    Abstract: Isolated membrane associated proteins which have a molecular weight of from about 30 kD to about 36 kilodaltons as determined by SDS-PAGE, are disclosed. The proteins have cis retinol dehydrogenase activity, such as 9, 11 or 13 cis retinol dehydrogenase activity, or cis activity at more than one position. Other trans-retinol dehydrogenases are also disclosed. Nucleic acid molecules which code for the proteins are also disclosed.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: June 4, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ulf Eriksson, Andras Simon, Anna Romert
  • Ku70—related methods
    Patent number: 6399298
    Abstract: This invention provides a method of diagnosing a predisposition to cancer in a subject comprising: (a) obtaining a nucleic acid sample from the subject; and; (b) determining whether one or more of the subject's Ku70 alleles or regulatory regions to those alleles are deleted or different from the wild type so as to reduce or eliminate the subject's expression of polypeptide having tumor suppressor activity. This invention also provides a method of assessing the severity of cancer in a subject comprising: (a) obtaining a nucleic acid sample from the subject; and (b) determining whether one or more of the subject's Ku70 alleles or regulatory regions to those alleles are deleted or different from the wild type so as to reduce or eliminate the subject's expression of polypeptide having tumor suppressor activity.
    Type: Grant
    Filed: June 30, 1999
    Date of Patent: June 4, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Gloria C. Li, Carlos Cordon-Cardo, Honghai Ouyang
  • Method for treating cancers which present antigen FB5 with humanized antibodies
    Patent number: 6391302
    Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: May 21, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
  • Isolated protein molecules which are members of the MAGE-B family
    Patent number: 6392016
    Abstract: The invention relates to members of the MAGE-B family of nucleic acid molecules. These molecules differ from the previously described MAGE nucleic acid molecules in that members of the MAGE-Xp family do not hybridize to the previously identified MAGE sequences. Further, the members of the MAGE-B family are found on the Xp arm of the X chromosome rather than on the Xq chromosome, as was the case with the previously identified MAGE genes.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: May 21, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Christophe Lurquin, Francis Brasseur, Thierry Boon-Falleur
  • Ma family polypeptides and anti-Ma antibodies
    Patent number: 6387639
    Abstract: Ma family polypeptides Ma1, Ma2, Ma3, Ma4 and Ma5 are disclosed, as are nucleic acids encoding the Ma family polypeptides, antibodies that bind to Ma family polypeptides, and methods of diagnosis of paraneoplastic syndromes, by assessing a test sample from an individual for the presence or absence, or amount, of antibodies to Ma family polypeptides.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: May 14, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Jerome B. Posner, Josep O. Dalmau, Myrna R. Rosenfeld
  • MAGE-10 encoding CDNA, the tumor rejection antigen precursor MAGE-10, antibodies specific to the molecule, and uses thereof
    Patent number: 6387698
    Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are part of the invention.
    Type: Grant
    Filed: August 18, 2000
    Date of Patent: May 14, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Donata Rimoldi, Victor Jongeneel, Pierre Coulie, Jean-Charles Cerrottini, Stefan Carrel, Daryl Reed
  • Methods for diagnosing multiple myeloma by determining rejection antigen precursors
    Patent number: 6387630
    Abstract: Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches to multiple myeloma are also disclosed.
    Type: Grant
    Filed: November 2, 2000
    Date of Patent: May 14, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Nicolas Van Baren, Francis Brasseur, Thierry Boon-Falleur
  • Antibodies to truncated VEGF-D and thereof
    Patent number: 6383484
    Abstract: The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the binding of VEGF-D to VEGFR-3 but does not interfere with the activity of VEGF mediated by VEGFR-2 or bind to VEGF-C. The invention provides pharmaceutical and diagnostic compositions and methods utilizing these antibodies.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Marc G. Achen, Steven Alan Stacker
  • Isolated decapeptides which bind to HLA molecules
    Patent number: 6384190
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: May 7, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules
    Patent number: 6379901
    Abstract: The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: April 30, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon-Falleur, Pierre van der Bruggen, Etienne De Plaen, Christophe Lurguin, Catia Traversari, Beatrice Gaugler, Benoit Van den Eynde
  • Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
    Patent number: 6372463
    Abstract: The invention relates to mutations in the gene encoding 11-cis retinal dehyrogenase. The mutations in the gene and in the resulting encoded protein are correlated to ocular disorders, such as fundus albipunctatus.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: April 16, 2002
    Assignees: The President & Fellows of Harvard College, Massachusette Eye & Ear Infirmary, Ludwig Institute for Cancer Research
    Inventors: András Simon, Ulf Eriksson, Thaddeus P. Dryja, Eliot L. Berson, Hioyuji Yamamoto
  • Synthesis of epothilones, intermediates thereto, analogues and uses thereof
    Patent number: 6369234
    Abstract: The present invention provides convergent processes for preparing epothilone A and B, desoxyepothilones A and B, and analogues thereof. Also provided are analogues related to epothilone A and B and intermediates useful for preparing same. The present invention further provides novel compositions based on analogues of the epothilones and methods for the treatment of cancer and cancer which has developed a multidrug-resistant phenotype.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: April 9, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Peter Bertinato, Dai-Shi Su, Dang Fang Meng, Ting-Chao Chou, Ted Kamenecka, Erik J. Sorensen, Aaron Balog, Kenneth A. Savin
  • Method for provoking proliferation of cytolytic T cells via the use of decapeptides which complex with HLA-A2 molecules
    Patent number: 6368857
    Abstract: Nonapeptides and decapeptides which bind to HLA molecules and provoke proliferation of cytolytic T cells are disclosed. The decapeptides terminate in Valine, and are restricted in their first three amino acid positions. Other useful nonapeptides are also disclosed.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: April 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Danila Valmori, Jean-Charles Cerottini, Pedro Romero
  • Smad2 phosphorylation and interaction with Smad4
    Patent number: 6368829
    Abstract: The invention describes amino acid residues of the Smad2 protein which are important for phosphorylation and activity, and Smad2 polypeptide fragments and biologically functional variants thereof. Included and dominant-negative variants of Smad2 and antibodies relating thereto. Also included are nucleic acids which encode such variants. Antibodies which selectively bind pathway-restricted Smad proteins phosphorylated at the C-terminal tail also are provided. Methods and products for using such nucleic acids and polypeptides also are provided.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: April 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Serhly Souchelnytskyi, Kiyoshi Tamaki, Ulla Engotröm, Christer Wornstedt, Ester Piek, Peter Bon Dijke, Carl-Henrik Heldin
  • MAGE-3 peptides presented by HLA class II molecules
    Patent number: 6369211
    Abstract: The invention describes the HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: April 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen
  • Isolation of a gene encoding human thyrotropin beta subunit
    Patent number: 6365127
    Abstract: The gene expressing the beta subunit of human thyroid stimulating hormone has been isolated. The gene has been incorporated into plasmid pBR322. Vectors can be used to transform cells which in turn produce pure beta subunits. The beta subunits can then be combined with the alpha subunit of human glycoprotein hormones to produce pure thyroid stimulating hormone.
    Type: Grant
    Filed: March 1, 2000
    Date of Patent: April 2, 2002
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ione A. Kourides, Graham Kerr Whitfield
  • Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
    Patent number: 6361946
    Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: March 26, 2002
    Assignees: Licentia Ltd, Ludwig Institute for Cancer Research
    Inventors: Kari Alitalo, Vladimir Joukov
  • Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof
    Patent number: 6358728
    Abstract: The invention relates to mutations in the gene encoding 11-cis retinal dehyrogenase. The mutations in the gene and in the resulting encoded protein are correlated to ocular disorders, such as fundus albipunctatus.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: March 19, 2002
    Assignees: The President & Fellows of Havard College, Massachusettes Eye & Ear Infirmary, Ludwig Institute for Cancer Research
    Inventors: András Simon, Ulf Eriksson, Thaddeaus P. Dryja, Eliot L. Berson, Hioyuji Yamamoto
  • Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses therefor
    Patent number: 6359117
    Abstract: The invention involves isolation of nucleic acid molecules, the expression of which are upregulated by interleukin-9. The amino acid sequences of the proteins which correspond to the nucleic acid molecules show some structural features of cytokines. In addition to the nucleic acid molecules and the proteins, various uses of the molecules are disclosed. The molecules are referred to as T cell inducible factors.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: March 19, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Laure Dumoutier, Jamila Louhed, Jean-Christophe Renauld